Time to make some sense of reimbursement in Europe
This article was originally published in Clinica
Executive Summary
Medical device reimbursement and funding policies in Europe are complex and perplexing. They represent a costly, moving target to manufacturers. The following excerpt from a paper given recently by Clinica's European regulatory affairs editor, Amanda Maxwell, at a European conference on Reimbursement*, looks at the problems and possible ways forward.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.